Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna cuts sales forecast on weaker vaccine demand
Moderna ( MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
After a rough 2024, Moderna lays out plans for 2025
In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
FiercePharma2d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling ...
GlobalData on MSN1d
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.
FiercePharma8d
After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
Moderna Stock Poised For Another Drop After Shaving Nearly $1 Billion Off Earnings Estimates
Drug maker Moderna 's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook ...
AOL5d
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
hospitalization,” Moderna CEO Stéphane Bancel said in a Sept. 30 news release. “By advancing our investigational norovirus vaccine into a pivotal Phase 3 trial, we are one step closer to ...